Poster will outline the design of R1’s ongoing global Phase 2b trial evaluating AP306 in patients with hyperphosphatemia AP306 is a potential first-in-class, oral, non-binder small molecule designed to inhibit all three intestinal phosphate transporters Phase 2b trial is enrolling across the US and China, with topline data expected in H1 2027 Redwood City, California […]
Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin® program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) […]
Lund, Sweden, July 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled “Don’t Be So Sensitive – Bringing Kidneys to the Over-Sensitized” with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at […]
Lund, Sweden, May 25, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. Read more…
13 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress (“EHA”), taking place 11-14 June 2026 in Stockholm, Sweden. Read more…
